Investors seeking momentum may have SPDR S&P Biotech ETF XBI on radar now. The fund recently hit a new 52-week high. Shares of XBI are up approximately 109% from their 52-week low of $62.94/share.
But could there be more gains ahead for this ETF? Let’s take a look at the fund and the near-term outlook to get a better idea of where it might be headed.
XBI in Focus
The underlying S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the U.S. common stocks listed on the NYSE, AMEX, NASDAQ National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. It charges 35 bps in fees (see all Health Care ETFs here).
Why the Move?
Shares of biotech companies rallied on back-to-back upbeat vaccine news. While Pfizer PFE and Moderna (NASDAQ:MRNA) MRNA already charged up markets with their success in COVID-19 vaccines in clinical trials, AstraZeneca (NASDAQ:AZN) AZN said on Nov 23 that its vaccine, developed in collaboration with the University of Oxford, showed an average 70% effectiveness. Plus, Sanofi (NASDAQ:SNY) and GlaxoSmithKline's (NYSE:GSK) as well as Johnson & Johnson (JNJ) are also working hard in the COVID-19 vaccine field.
More Gains Ahead?
The fund has a positive weighted alpha of 49.50. So, there is a decent outlook ahead for those who want to ride this surging ETF a shade further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Pfizer Inc. (NYSE:PFE): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
SPDR S&P Biotech ETF (XBI): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report